Kidney Biopsy Market Size was valued at USD 2.2 Billion in 2023. The kidney biopsy market industry is projected to grow from USD 2.31 Billion in 2024 to USD 3.31 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.57% during the forecast period (2024 - 2032). The kidney biopsy market share may increase as a result of a few market drivers. Due to a rise in the need for novel methods of chronic disease diagnosis as well as an increase in the volume of biopsy procedures, the market for kidney biopsies has experienced tremendous growth recently. Additionally, the rising frequency of renal illnesses, the growing need for better diagnostic and therapeutic approaches, and ongoing technical improvements are all projected to boost market expansion during the study period.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Kidney cancer can strike individuals of any age. Kidney cancer has a wide range of signs and symptoms, but they can be difficult to distinguish from other, more common medical problems since they are non-specific. In its early stages, kidney cancer typically exhibits neither signs nor symptoms. Over time, signs and symptoms could include blood in the urine, which could be pink, red, or cola-colored; persistent back or side pain; loss of appetite; unexplained weight loss; exhaustion; and fever. Adults are most likely to develop kidney cancer than any other cancer form. An aggressive kidney cancer known as a Wilms tumor is more common in young children. The 14th most prevalent cancer in the world is renal cancer, also known as kidney cancer or renal cell adenocarcinoma. It ranks 14th among females and ninth among men. The number of kidney cancer diagnoses increased to around 30,000 in 2020. Kidney cancer cases are on the rise worldwide and are becoming a serious socioeconomic problem as a result of multiple risk factors like smoking, obesity, high blood pressure (hypertension), or a family history of the disease. In light of this, the growing number of kidney cancer patients is driving growth in the worldwide kidney biopsy market CAGR by increasing demand for renal biopsy.
The growth and development of the kidney biopsy market have been greatly influenced by improvements in biopsy methods. These developments have enhanced the safety, accuracy, and patient experience of the biopsy technique. The market for biopsy devices is being shaped by robotically assisted systems, which also assist in preventing post-biopsy problems. Medical authorities have been approving the equipment to make the process simpler. Robot-assisted biopsy is done to boost the precision and accuracy of the biopsy process. Moreover, image-guided kidney biopsies, such as those performed using ultrasonography or computed tomography, are now more common. These procedures provide accurate collection and reduce the chance of problems by using real-time imaging to guide the needle exactly to the targeted kidney location. Thus, driving the kidney biopsy market revenue.
The kidney biopsy market segmentation, based on end-user includes Hospitals & Clinics, Urology Centers, Tertiary Care Centers and Others. The hospitals & clinics segment dominated the market. The majority of kidney biopsy operations are carried out in hospitals & clinics. In addition to diagnostic procedures like kidney biopsies, they offer a wide range of healthcare services. Kidney biopsies can be completed in hospitals thanks to its infrastructure, medical staff, and equipment.
The kidney biopsy market segmentation, based on indication, includes Kidney Failure, Kidney Transplant, Hematuria and Proteinuria. The kidney transplant category generated the most income. In the context of kidney transplantation, kidney biopsies are frequently conducted. Prior to transplantation, biopsies are performed to evaluate the appropriateness of the donor organ and guarantee compatibility with the recipient. In order to monitor the transplanted kidney's health and functionality, spot any signs of rejection or other issues, and inform treatment choices, post-transplant biopsies are carried out.
The kidney biopsy market segmentation, based on type includes Percutaneous Biopsy and Surgical Biopsy. The percutaneous biopsy segment dominated the market. The most frequent and commonly utilised type of kidney biopsy is percutaneous. In order to get a tissue sample, a biopsy needle must be inserted through the skin and into the kidney. Typically, local anesthesia is used during this surgery, and imaging methods like CT scans or ultrasounds are used to accurately pinpoint the biopsy location.
Figure 1 Kidney Biopsy Market, by Type, 2023 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American kidney biopsy market area will dominate this market. The high costs of healthcare, government funding of R&D, widespread use of technologically advanced medical devices for kidney disease diagnosis and treatment, an increase in the number of kidney disease patients, diabetes, and other risk factors for renal failure, as well as the high spending on health care, are all factors driving the growth of the regional market. The number of patients with diabetes, kidney disease, and other risk factors for renal failure is rising, which is also driving the market. Expanding usage of new technologies for treating ailments, favorable reimbursement rules, and significant investments in their development will propel market growth.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 KIDNEY BIOPSY MARKET SHARE BY REGION 2023 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe kidney biopsy market accounts for the second-largest market share. The growth of the regional market is attributed to the availability of research funding, rising government support for R&D, increasing emphasis on the development of cutting-edge diagnostic tools in urology, and an increase in the number of specialty services offered by various healthcare providers. Additionally, it is anticipated that increased applications, sizable expenditures, and favorable reimbursement rules will all improve the performance of the regional market. Further, the German kidney biopsy market held the largest market share, and the UK kidney biopsy market was the fastest growing market in the European region
The Asia-Pacific Kidney biopsy Market is expected to grow at the fastest CAGR from 2024 to 2032 due to the rising prevalence of diabetes and the rise in kidney transplant surgeries performed in urology clinics. The market is also fueled by increased healthcare spending and the quickly expanding healthcare technology sector. Additionally, growing demand for high-quality medical devices is probably going to result in higher use of cutting-edge technology, speeding up market expansion in this sector. Moreover, China’s kidney biopsy market held the largest market share, and the Indian kidney biopsy market was the fastest growing market in the Asia-Pacific region.
Kidney Biopsy Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the kidney biopsy market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, kidney biopsy industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the kidney biopsy industry to benefit clients and increase the market sector. In recent years, the kidney biopsy industry has offered some of the most significant advantages to market. Major players in the kidney biopsy market attempting to increase market demand by investing in research and development operations include Boston Scientific Corporation (U.S.), Cook Medical (U.S.), C R Bard, Inc. (U.S.), Devicor Medical Products Inc. (U.S.), Hologic Inc. (U.S.), Intact Medical Corporation (U.S.), Precision Biopsy, LLC (U.S.), Scion Medical Technologies LLC (U.S.), Integra LifeSciences Corporation (U.S.), Creganna (U.S.), Focal Therapeutics, Inc. (U.S.), CareFusion (U.S.), Argon Medical Devices, Inc. (U.S.) and others.
With its headquarters in Plano, Texas, Argon Medical is a maker of speciality medical goods on a scale. Vascular surgery, interventional cardiology, interventional radiology, and oncology all have a variety of medical equipment available from Argon. The Argon brand is known for top-of-the-line solutions that enhance patient outcomes through percutaneous, image-guided operations. Argon supports its international customers through a direct sales organisation and through enduring connections with OEMs, strategic partners, and medical device distributors by utilizing a well-established sales and marketing infrastructure. Over 1000 people work at Argon worldwide in manufacturing facilities in Athens, Texas, Wheeling, Illinois, Rochester, New York, and Portage, Wisconsin.
Cook Medical Inc., a division of Cook Group Inc., is a manufacturer, distributor, and developer of medical devices for minimally invasive procedures. Catheters, grafts, stents, plugs, wire guides, needles, balloons, feeding tubes, and extractors are among the main items produced by the company. Among other specialties, it provides goods and services in anesthesiology, bariatrics, cardiothoracic, general, gynecologic oncology, gynecology, neurosurgery, colorectal, endovascular, peripheral cardiology, plastic surgery, traumatology, urogynecology, and urology.
Key Companies in the kidney biopsy market include
Kidney Biopsy Industry Developments
September 2021 Natera, Inc., a leader in cell-free DNA (cfDNA) testing, recently unveiled Prospera with Quantification, the only cfDNA test for kidney rejection that provides three values on each report total cfDNA, the percentage of donor-derived cfDNA, and the amount of donor-derived cfDNA (dd-cfDNA). Comparatively to using the dd-cfDNA fraction alone, it has been suggested that combining these three measures will increase sensitivity for determining transplant rejection.
May 2021 AVROBIO, Inc., a pioneer in the field of clinical-stage gene therapy, provided an update on its regulatory preparations for AVR-RD-01, the first investigational lentiviral gene therapy for Fabry disease. The change is in response to the most recent regulatory advancement for Fabry disease treatments in the US.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 2.2 Billion |
| Market Size 2024 | USD 2.31 Billion |
| Market Size 2032 | USD 3.31 Billion |
| Compound Annual Growth Rate (CAGR) | 4.57% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | End-User, Indication, Type and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Boston Scientific Corporation (U.S.), Cook Medical (U.S.), C R Bard, Inc. (U.S.), Devicor Medical Products Inc. (U.S.), Hologic Inc. (U.S.), Intact Medical Corporation (U.S.), Precision Biopsy, LLC (U.S.), Scion Medical Technologies LLC (U.S.), Integra LifeSciences Corporation (U.S.), Creganna (U.S.), Focal Therapeutics, Inc. (U.S.), CareFusion (U.S.), Argon Medical Devices, Inc. (U.S.) and others |
| Key Market Opportunities | Established market players in flourishing nations drive ization by providing new goods and services to developing nations and rising economies |
| Key Market Dynamics | Increasing number of biopsy proceduresRising demand for new techniques for diagnosis of chronic diseases |
Kidney Biopsy Market Highlights:
Frequently Asked Questions (FAQ) :
The kidney biopsy market size was valued at USD 2.2 Billion in 2023.
The market is projected to grow at a CAGR of 4.57% during the forecast period, 2024-2032.
North America had the largest share in the market.
The key players in the market are Boston Scientific Corporation (U.S.), Cook Medical (U.S.), C R Bard, Inc. (U.S.), Devicor Medical Products Inc. (U.S.), Hologic Inc. (U.S.), Intact Medical Corporation (U.S.), Precision Biopsy, LLC (U.S.), Scion Medical Technologies LLC (U.S.), Integra LifeSciences Corporation (U.S.), Creganna (U.S.), Focal Therapeutics, Inc. (U.S.), CareFusion (U.S.), Argon Medical Devices, Inc. (U.S.) and others.
The percutaneous biopsy category dominated the market in 2022.
The kidney transplant category had the largest share in the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
